$GRTX
Galera Therapeutics, Inc.

2024 Q4 Form 10-Q Financial Statement

#000119312524277849 Filed on December 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3 2023 Q4
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.987M
YoY Change -60.43%
% of Gross Profit
Research & Development $305.0K $3.189M
YoY Change -94.99% -60.81%
% of Gross Profit
Depreciation & Amortization $219.0K
YoY Change 742.31%
% of Gross Profit
Operating Expenses $305.0K $5.176M
YoY Change -94.99% -60.66%
Operating Profit -$5.908M
YoY Change -55.9%
Interest Expense $0.00 -$411.0K
YoY Change -100.0% -86.63%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$5.784M -$5.587M
YoY Change -61.62% -65.64%
Income Tax $200.0K
% Of Pretax Income
Net Earnings -$5.581M -$5.587M
YoY Change -62.97% -65.49%
Net Earnings / Revenue
Basic Earnings Per Share -$0.10
Diluted Earnings Per Share -$0.10 -$0.10
COMMON SHARES
Basic Shares Outstanding 54.39M 54.39M 54.39M
Diluted Shares Outstanding 54.39M

Balance Sheet

Concept 2024 Q4 2024 Q3 2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $18.26M
YoY Change -42.22%
Cash & Equivalents $8.455M $18.26M
Short-Term Investments $0.00
Other Short-Term Assets $3.372M
YoY Change -51.4%
Inventory
Prepaid Expenses $0.00 $1.450M
Receivables
Other Receivables
Total Short-Term Assets $8.899M $21.63M
YoY Change -71.52% -43.87%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00 $1.283M
YoY Change -100.0% 192.92%
Goodwill $0.00 $881.0K
YoY Change -100.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.000K $90.00K
YoY Change -99.9% -95.22%
Total Long-Term Assets $2.000K $4.512M
YoY Change -99.97% -17.98%
TOTAL ASSETS
Total Short-Term Assets $8.899M $21.63M
Total Long-Term Assets $2.000K $4.512M
Total Assets $8.901M $26.14M
YoY Change -76.44% -40.64%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $296.0K $1.375M
YoY Change -92.03% -61.6%
Accrued Expenses $618.0K $3.582M
YoY Change -92.96% -63.28%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $914.0K $4.957M
YoY Change -92.76% -62.95%
LONG-TERM LIABILITIES
Long-Term Debt $151.0M
YoY Change 8.17%
Other Long-Term Liabilities $1.117M
YoY Change
Total Long-Term Liabilities $152.2M
YoY Change 8.97%
TOTAL LIABILITIES
Total Short-Term Liabilities $914.0K $4.957M
Total Long-Term Liabilities $152.2M
Total Liabilities $152.0M $157.3M
YoY Change -7.53% 2.68%
SHAREHOLDERS EQUITY
Retained Earnings -$451.4M -$437.4M
YoY Change 4.54% 15.62%
Common Stock $308.4M $306.2M
YoY Change 1.02% 13.77%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$143.1M -$131.2M
YoY Change
Total Liabilities & Shareholders Equity $8.901M $26.14M
YoY Change -76.44% -40.64%

Cashflow Statement

Concept 2024 Q4 2024 Q3 2023 Q4
OPERATING ACTIVITIES
Net Income -$5.581M -$5.587M
YoY Change -62.97% -65.49%
Depreciation, Depletion And Amortization $219.0K
YoY Change 742.31%
Cash From Operating Activities -$9.918M
YoY Change -28.88%
INVESTING ACTIVITIES
Capital Expenditures $9.000K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $3.982M
YoY Change 43.29%
Cash From Investing Activities $3.973M
YoY Change 42.97%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -234.0K
YoY Change -108.66%
NET CHANGE
Cash From Operating Activities -9.918M
Cash From Investing Activities 3.973M
Cash From Financing Activities -234.0K
Net Change In Cash -6.179M
YoY Change -27.0%
FREE CASH FLOW
Cash From Operating Activities -$9.918M
Capital Expenditures $9.000K
Free Cash Flow -$9.927M
YoY Change -28.81%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001563577
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39114
dei Entity Registrant Name
EntityRegistrantName
Galera Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-1454898
dei Entity Address Address Line1
EntityAddressAddressLine1
45 Liberty Blvd, Suite 230
dei Entity Address City Or Town
EntityAddressCityOrTown
Malvern
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19355
dei City Area Code
CityAreaCode
610
dei Local Phone Number
LocalPhoneNumber
725-1500
dei Trading Symbol
TradingSymbol
GRTX
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
54392170
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8455000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18257000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
444000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3372000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
8899000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
21629000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
71000
CY2024Q3 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
0
CY2023Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
2258000
CY2024Q3 us-gaap Goodwill
Goodwill
0
CY2023Q4 us-gaap Goodwill
Goodwill
881000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1212000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
90000
CY2024Q3 us-gaap Assets
Assets
8901000
CY2023Q4 us-gaap Assets
Assets
26141000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
296000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1375000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
618000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3449000
CY2024Q3 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
0
CY2023Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
133000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
914000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4957000
CY2024Q3 us-gaap Royalty Guarantees Commitments Amount
RoyaltyGuaranteesCommitmentsAmount
151049000
CY2023Q4 us-gaap Royalty Guarantees Commitments Amount
RoyaltyGuaranteesCommitmentsAmount
151049000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1117000
CY2024Q3 us-gaap Deferred Tax Liabilities Derivatives
DeferredTaxLiabilitiesDerivatives
0
CY2023Q4 us-gaap Deferred Tax Liabilities Derivatives
DeferredTaxLiabilitiesDerivatives
203000
CY2024Q3 us-gaap Liabilities
Liabilities
151963000
CY2023Q4 us-gaap Liabilities
Liabilities
157326000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
54392170
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
54392170
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
54392170
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
54392170
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
54000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
54000
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
308316000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
306167000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-451432000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-437406000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-143062000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-131185000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8901000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
26141000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
305000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6093000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3223000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20926000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3439000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4994000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9307000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20849000
CY2024Q3 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
2258000
CY2023Q3 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0
us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
2258000
us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0
CY2024Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
881000
CY2023Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
881000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2024Q3 us-gaap Litigation Settlement Gain
LitigationSettlementGain
975000
CY2023Q3 us-gaap Litigation Settlement Gain
LitigationSettlementGain
0
us-gaap Litigation Settlement Gain
LitigationSettlementGain
975000
us-gaap Litigation Settlement Gain
LitigationSettlementGain
0
CY2024Q3 us-gaap Restructuring Charges
RestructuringCharges
0
CY2023Q3 us-gaap Restructuring Charges
RestructuringCharges
2309000
us-gaap Restructuring Charges
RestructuringCharges
0
us-gaap Restructuring Charges
RestructuringCharges
2309000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5908000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-13396000
us-gaap Operating Income Loss
OperatingIncomeLoss
-14694000
us-gaap Operating Income Loss
OperatingIncomeLoss
-44084000
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
126000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
411000
us-gaap Investment Income Interest
InvestmentIncomeInterest
471000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1300000
CY2024Q3 us-gaap Interest Expense
InterestExpense
0
CY2023Q3 us-gaap Interest Expense
InterestExpense
2087000
us-gaap Interest Expense
InterestExpense
0
us-gaap Interest Expense
InterestExpense
10709000
CY2024Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-2000
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-1000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-6000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-2000
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5784000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-15073000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-14229000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-53495000
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-203000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-203000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-5581000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-15073000
us-gaap Net Income Loss
NetIncomeLoss
-14026000
us-gaap Net Income Loss
NetIncomeLoss
-53495000
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.1
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.1
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.33
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.33
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.26
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.26
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.3
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.3
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54392170
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54392170
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45477952
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
45477952
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
54392170
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
54392170
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41234679
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41234679
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-5581000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-15073000
us-gaap Net Income Loss
NetIncomeLoss
-14026000
us-gaap Net Income Loss
NetIncomeLoss
-53495000
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-5000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
22000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5581000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15078000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14026000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-53473000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-131185000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
875000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-4381000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-134691000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
723000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-4064000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-138032000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
551000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-5581000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-143062000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-109181000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1458000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
184000
grtx Common Stock Issuance Costs
CommonStockIssuanceCosts
2403000
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
27598000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
38000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-17710000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-97613000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1525000
CY2023Q2 grtx Stock Issued During Period Value Common Stock Warrants Exercised1
StockIssuedDuringPeriodValueCommonStockWarrantsExercised1
1812000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-11000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-20712000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-114999000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1390000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4000
CY2023Q3 grtx Stock Issued During Period Value Common Stock Warrants Exercised1
StockIssuedDuringPeriodValueCommonStockWarrantsExercised1
197000
CY2023Q3 grtx Sale Of Shares Under Open Market Sale Agreement Value
SaleOfSharesUnderOpenMarketSaleAgreementValue
1933000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-5000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-15073000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-126553000
us-gaap Profit Loss
ProfitLoss
-14026000
us-gaap Profit Loss
ProfitLoss
-53495000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
20000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
44000
us-gaap Paid In Kind Interest
PaidInKindInterest
0
us-gaap Paid In Kind Interest
PaidInKindInterest
10709000
us-gaap Share Based Compensation
ShareBasedCompensation
2149000
us-gaap Share Based Compensation
ShareBasedCompensation
4373000
us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
2258000
us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
881000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-203000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-48000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
72000
grtx Refundable Pdufa Fees
RefundablePdufaFees
0
grtx Refundable Pdufa Fees
RefundablePdufaFees
3242000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2928000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1133000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-88000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-37000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1079000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
134000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2832000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-970000
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
38000
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
68000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9806000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-34933000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
0
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
22627000
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
0
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
45995000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
4000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
50000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
4000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
23318000
grtx Proceeds From Sale Of Common Stock And Common Stock Warrants In Registered Direct Offering
ProceedsFromSaleOfCommonStockAndCommonStockWarrantsInRegisteredDirectOffering
0
grtx Proceeds From Sale Of Common Stock And Common Stock Warrants In Registered Direct Offering
ProceedsFromSaleOfCommonStockAndCommonStockWarrantsInRegisteredDirectOffering
27598000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1933000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2009000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
188000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
31728000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-9802000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
20113000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18257000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4316000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8455000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24429000
grtx Derecognition Of Lease Liability And Right Of Use Asset Due To Lease Termination Operating Lease
DerecognitionOfLeaseLiabilityAndRightOfUseAssetDueToLeaseTerminationOperatingLease
1212000
grtx Derecognition Of Lease Liability And Right Of Use Asset Due To Lease Termination Operating Lease
DerecognitionOfLeaseLiabilityAndRightOfUseAssetDueToLeaseTerminationOperatingLease
0
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
0
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
1310000
grtx Sale Of Property And Equipment In Exchange For Prepaid Future Services
SaleOfPropertyAndEquipmentInExchangeForPrepaidFutureServices
0
grtx Sale Of Property And Equipment In Exchange For Prepaid Future Services
SaleOfPropertyAndEquipmentInExchangeForPrepaidFutureServices
319000
CY2023Q3 grtx Number Of Reduction In Companys Current Workforce Employees
NumberOfReductionInCompanysCurrentWorkforceEmployees
22
CY2023Q3 grtx Workforce Reduction Rate
WorkforceReductionRate
0.70
CY2024Q3 grtx Number Of Reduction In Companys Current Workforce Employees
NumberOfReductionInCompanysCurrentWorkforceEmployees
3
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-451400000
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Use of estimates </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of unaudited interim consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the unaudited interim consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the unaudited interim consolidated financial statements in the period they are determined to be necessary. Significant areas that require management’s estimates include share-based compensation assumptions, royalty purchase liability assumptions and accrued research and development expenses. </div>
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
200000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2023Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2023Q3 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0
us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0
CY2024Q3 us-gaap Litigation Settlement Gain
LitigationSettlementGain
975000
CY2023 us-gaap Restructuring Charges
RestructuringCharges
2300000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19196571
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20237782
us-gaap Fair Value Liabilities Measured On Recurring Basis Debt Instrument Valuation Techniques Change In Technique Quantification Of Effect
FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect
0
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
0
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1450000
CY2024Q3 us-gaap Prepaid Insurance
PrepaidInsurance
151000
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1302000
CY2024Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
293000
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
620000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
444000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3372000
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
0
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
530000
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
0
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
459000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
71000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
20000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
44000
CY2024Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
151000
CY2023Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
121000
CY2024Q3 grtx Accrued Restructuring Costs Current
AccruedRestructuringCostsCurrent
0
CY2023Q4 grtx Accrued Restructuring Costs Current
AccruedRestructuringCostsCurrent
443000
CY2024Q3 grtx Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
201000
CY2023Q4 grtx Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
2672000
CY2024Q3 grtx Accrued Professional Fees And Other Expenses Current
AccruedProfessionalFeesAndOtherExpensesCurrent
266000
CY2023Q4 grtx Accrued Professional Fees And Other Expenses Current
AccruedProfessionalFeesAndOtherExpensesCurrent
213000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
618000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3449000
CY2024Q3 us-gaap Debt Instrument Interest Rate Effective Percentage
DebtInstrumentInterestRateEffectivePercentage
0
CY2024Q3 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P6Y
CY2024Q3 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
4700000
CY2024Q3 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.054
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1212000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
133000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1117000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
0
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1250000
CY2024Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
451000
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
54000
us-gaap Operating Lease Expense
OperatingLeaseExpense
559000
us-gaap Operating Lease Expense
OperatingLeaseExpense
138000
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
451000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
54000
us-gaap Operating Lease Cost
OperatingLeaseCost
559000
us-gaap Operating Lease Cost
OperatingLeaseCost
138000
us-gaap Operating Lease Payments
OperatingLeasePayments
597000
us-gaap Operating Lease Payments
OperatingLeasePayments
97000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1310000
grtx Derecognition Of Lease Liability And Right Of Use Asset Due To Lease Termination Operating Lease
DerecognitionOfLeaseLiabilityAndRightOfUseAssetDueToLeaseTerminationOperatingLease
1212000
grtx Derecognition Of Lease Liability And Right Of Use Asset Due To Lease Termination Operating Lease
DerecognitionOfLeaseLiabilityAndRightOfUseAssetDueToLeaseTerminationOperatingLease
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
14320000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
14320000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Per Share Weighted Average Price Of Shares Purchased
ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
2.095
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
27600000
CY2023Q1 us-gaap Warrant Exercise Price Increase
WarrantExercisePriceIncrease
1.97
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P5Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
13300000
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
551000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1390000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2149000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4373000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5739488
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.85
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y7M6D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
393578
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.09
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5345910
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.98
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y4M24D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4434256
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.67
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y9M18D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
5345910
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
5.98
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P5Y4M24D
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1800000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y7M6D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.66
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y2M12D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.953
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0405
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q3 us-gaap Restructuring Charges
RestructuringCharges
2300000
CY2023Q4 us-gaap Restructuring Reserve
RestructuringReserve
443000
us-gaap Restructuring Reserve Accrual Adjustment1
RestructuringReserveAccrualAdjustment1
0
us-gaap Payments For Restructuring
PaymentsForRestructuring
443000
CY2024Q3 us-gaap Restructuring Reserve
RestructuringReserve
0
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001193125-24-277849-index-headers.html Edgar Link pending
0001193125-24-277849-index.html Edgar Link pending
0001193125-24-277849.txt Edgar Link pending
0001193125-24-277849-xbrl.zip Edgar Link pending
d914517d10q.htm Edgar Link pending
d914517dex101.htm Edgar Link pending
d914517dex311.htm Edgar Link pending
d914517dex312.htm Edgar Link pending
d914517dex321.htm Edgar Link pending
d914517dex322.htm Edgar Link pending
d914517d10q_htm.xml Edgar Link completed
Financial_Report.xlsx Edgar Link pending
grtx-20240930.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
grtx-20240930_cal.xml Edgar Link unprocessable
grtx-20240930_def.xml Edgar Link unprocessable
grtx-20240930_pre.xml Edgar Link unprocessable
grtx-20240930_lab.xml Edgar Link unprocessable
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending